# Perioperative Intervention to Reduce Metastatic Processes in Pancreatic Cancer Patients Undergoing Curative Surgery

> **NCT03838029** · PHASE2 · UNKNOWN · sponsor: **Assaf-Harofeh Medical Center** · enrollment: 210 (estimated)

## Conditions studied

- Pancreatic Neoplasms

## Interventions

- **DRUG:** Propranolol and etodolac
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03838029
- **Lead sponsor:** Assaf-Harofeh Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-20
- **Primary completion:** 2026-01
- **Final completion:** 2026-01
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2019-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03838029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03838029, "Perioperative Intervention to Reduce Metastatic Processes in Pancreatic Cancer Patients Undergoing Curative Surgery". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT03838029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*